cyproterone and Flushing

12 patients with troublesome hot flushes after orchidectomy (as a primary treatment for prostatic carcinoma) were treated with cyproterone acetate or placebo in a double-blind cross-over trial. The frequency of hot flushes was significantly reduced during the three weeks that cyproterone acetate (100 mg three times a day) was given. 5 patients complained of lassitude while on cyproterone acetate, but in none was it necessary to discontinue treatment.

Topics: Aged; Androgen Antagonists; Castration; Climacteric; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Double-Blind Method; Flushing; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation

Out of 17 patients who had been submitted to subcapsular orchidectomy as the primary treatment of cancer of the prostate, postorchiectomy flushing was found in eight, corresponding to 47%. Six of the patients were treated with cyproterone acetate in a dosage of 50-100 mg daily. In all of these clinically significant reduction in the frequency and duration of the flushing was found. In four out of five patients with possible recurrent flushing after withdrawal of cyproterone acetate, recommencement of the treatment proved necessary. Administration of cyproterone acetate appears to be equally effective in a dosage of 100 mg daily as in a dosage of 300 mg daily and this reduces the side effects and expenses considerably. If it is possible to obtain a more extensive patient material without hormone treatment, a placebo-controlled investigation with the reduced dosage is desirable.

Topics: Aged; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flushing; Humans; Male; Middle Aged; Orchiectomy; Postoperative Complications; Prostatic Neoplasms

Topics: Androgen Antagonists; Castration; Cyproterone; Cyproterone Acetate; Flushing; Humans; Male